Novartis' Certican™ patent upheld by European Patent Office
Investigational transplant drug Certican is 'inventive' and patentable
This is the latest chapter in the European patent dispute with AHP, who allege that Certican infringes patent rights it has licensed.
Novartis is pleased with the latest, very significant development, which underlines non-infringement decisions in Novartis' favour taken recently by the UK Court of Appeal and the District Court in the Hague.
Certican, (also known as 'RAD' or the non-proprietary name 'everolimus') is a novel immunosuppressive molecule, independently invented, patented and developed by Novartis as part of its longstanding commitment towards improving the outcome of transplantation and the quality of life in transplant patients. Novartis is committed to continuing the Certican global development program and to providing a product for worldwide clinical use at the earliest possible time.
Most read news
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.